MedDataX Logo

Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia

NCT ID: NCT00749970

Last Updated: 2010-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-07-31

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational, short-term prospective, multicenter study to assess psychometric properties of the Spanish version of SWN-K scale in patients with schizophrenia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Schizoaffective Disorder Schizophreniform Disorder

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

schizophrenia subjective well-being psychometric validation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder (DSM-IV TR criteria)
* Stabilized out-patients
* Under treatment with an oral antipsychotic drug

Exclusion Criteria

* Administration of a depot antipsychotic drug
* Participation in another clinical trial within 4 weeks prior to enrolment into this study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Alicante, , Spain

Site Status

Research site

Barcelona, , Spain

Site Status

Research site

Burgos, , Spain

Site Status

Research Site

Córdoba, , Spain

Site Status

Research Site

Granada, , Spain

Site Status

Research site

Madrid, , Spain

Site Status

Research Site

Mallorca, , Spain

Site Status

Research Site

Salamanca, , Spain

Site Status

Research Site

Seville, , Spain

Site Status

Research site

Tarragona, , Spain

Site Status

Research Site

Valencia, , Spain

Site Status

Research Site

Valladolid, , Spain

Site Status

Research Site

Vitoria-Gasteiz, , Spain

Site Status

Research Site

Zaragoza, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-NES-DUM-2008/1

Identifier Type: -

Identifier Source: org_study_id